Anti-inflammatory drugs may prevent death but fail to speed up recovery in COVID-19 patients

The key points of the study are:

• Hospitalized patients 18 years or older with confirmed SARS-CoV-2 infection within 14 days
• The evidence of pulmonary involvement underwent randomization (October 2020 and December 2021).
• Dosages are a Single infusion of abatacept at 10 mg/kg; maximum dose, 1000 mg, 5 mg/kg infliximab or cenicriviroc 28-day course orally, 300-mg loading dose followed by 150 mg twice daily.
• Number of participants: 1971 of mean age of 54.8 years and 1218 men.
• The primary endpoint was not significantly different for abatacept, cenicriviroc or infliximab with recovery rate ratio or RRR, of 1.12, 1.01 and 1.12 respectively when compared with placebo.
• All-cause 28-day mortality for abatacept vs placebo, cenicriviroc vs placebo and infliximab vs placebo was 11% vs 15.1%, 13.8 % vs 11.9 % and 10.1 % vs 14.5 %.
• The odds ratio were 0.62, 1.18 and 0.59 respectively.
• In all 3 substudies, safety outcomes were comparable between active treatment and placebo, including secondary infections,

The study limitations are questions on whether results are limited to the variants represented at that time, unavailability of data on participant vaccination status, and chances of negative results.

Based on the study’s results, researchers concluded that in COVID-19 pneumonia, time to recovery among hospitalized patients is no different for abatacept, cenicriviroc, or infliximab vs placebo

Further reading:

https://jamanetwork.com/journals/jama/fullarticle/2807333